Immunovant, the biotech company behind batoclimab, will continue to prioritize its next-gen asset, IMVT-1402, over the chronic autoimmune disorder treatment. The decision comes after a Phase III trial of batoclimab showed promise in improving aspects of daily living for patients with myasthenia gravis.
The data from the trial revealed significant improvements for patients taking high doses of batoclimab, with a 5.6-point increase on a scale measuring aspects of living with myasthenia gravis. However, analysts say the results support the focus on IMVT-1402, which has been cleared for clinical testing and will soon enter pivotal trials.
Immunovant had already signaled its preference for IMVT-1402 last year, and the company’s shift is not surprising to investors. Shares initially lost value but recovered around 11 a.m. ET, closing at $20.27, an 8% increase over the prior day’s close.
The biotech firm will use learnings from batoclimab tests to inform its IMVT-1402 pivotal trials, which are expected to roll out “imminently” in both myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CDIP).
Source: https://www.biospace.com/drug-development/immunovant-will-drop-one-myasthenia-gravis-asset-continuing-to-favor-another